
Nanothea S.A.
Research and experimental development in natural sciences and engineering
Overview
Nanothea is a company that develops innovative radiopharmaceuticals for the diagnosis and treatment of cancer. They focus on creating precise methods using radioisotopes combined with nanoparticles and targeting conjugates to improve the effectiveness of radiotherapy while minimizing side effects. Their products are designed to ensure non-toxic, FDA-approved materials for safe therapeutic delivery directly to tumors.
Financials
Revenue history (in k)
Financial insights
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
- The statement flags a going concern risk. Zarząd wskazał znaczącą niepewność co do kontynuacji działalności, wynikającą m.in. z wysokiego ryzyka projektów badawczo-rozwojowych, braku przychodów ze sprzedaży projektów oraz konieczności ciągłego pozyskiwania finansowania.
From the notes
| Profit allocation | Loss to be covered | |
| Revenue structure | Produkty | |
| Shareholders |
|
Filing timeliness
1 of 6 financial statements was filed late (for 2023, 21 days late). All were audited by a statutory auditor.
- 202514/07/2026
- 202414/07/2025
- 202305/08/2024
- 202206/07/2023
- 202130/06/2022
- 202001/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Radiopharmaceuticals
- Nanoparticles for cancer diagnostics
- Conjugates for cancer diagnostics
- Cancer diagnostic methods
- Cancer radiotherapy methods
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
- Analytics and marketing
- Google Analytics
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-01-11.
16 1090 1056 0000 0001 3132 3692
59 1090 1870 0000 0001 3704 2883
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 5, 2017 | Commercial Companies Code notice | |
| Apr 19, 2016 | Commercial Companies Code notice |
Public aid
6 public aid cases recorded, with a total value of $1,695,336.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 17, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy | |
| Apr 24, 2017 | Aid for research and development projects: industrial research | $299.3K$299,290 | MARSZAŁEK MAZOWIECKI | |
| Apr 24, 2017 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $6,814$6,814 | MARSZAŁEK MAZOWIECKI |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-10-01 | Biopolymer nanoparticles as carriers of radioactive isotopes for the early diagnosis of cancer | $1.3M$1,329,441 | Operational Programme Smart Growth | |
| 2016-06-07 | Development of biopolymer nanoparticles for precise diagnosis and targeted therapy of prostate cancer using radioisotopes | $293.6K$293,553 | Regional Operational Programme for the Mazowieckie Voivodeship for 2014-2020 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Möbius Lab sp. z o.o. | $875.42 | mobiuslab.pl | ||
| Bioinfobank S.A. | $688.06 | bioinfobank.com | ||
| Resolvi sp. z o.o. | $335.91 | resolvi.pl | ||
| Fungotech sp. z o.o. | $187.68 | fungo.tech |
Change history
| Date | Event | |
|---|---|---|
| 2025-09-23 | Switch to PKD 2025 (6 PKD 2007 codes → 5 PKD 2025 codes) | |
| 2024-12-24 | Share capital increase (282,944.00 PLN → 298,645.00 PLN) | |
| 2023-09-07 | Share capital increase (252,944.00 PLN → 282,944.00 PLN) | |
| 2023-06-12 | Share capital increase (157,063.00 PLN → 252,944.00 PLN) | |
| 2022-05-26 | Share capital increase (153,123.00 PLN → 157,063.00 PLN) |
FAQ
Last updated: 2026-07-17